TORONTO, ONTARIO – December 4, 2020 – OB Pharmaceuticals, Inc., announced today the company will present its poster on its lead molecule, TD567 in preclinical studies of its effects on seizures resulting from traumatic brain injury (TBI) at the American Epilepsy Society Annual Meeting being held virtually from December 4 through December 8. "TD567 continues to demonstrate great potential as a lead molecule, not only for its efficacy for these often intractable seizures but also for its excellent profile as a drug candidate", said Dr. Larry Mahan, CEO. Data will be presented for 3 different preclinical TBI models comparing TD567 against standard of care antiepileptic drugs.
The details for the poster presentation are as follows and are available online at AES 2020 for review.
Abstract No. 850: TD567, A Novel Carboxyphenolcyclohexenone as a Drug Candidate for the Treatment of Post-traumatic Epilepsy
About OB Pharmaceuticals
OB Pharmaceuticals is an early stage biopharmaceutical company dedicated to improving the lives of individuals with epilepsy through the development of first-in-class therapies that prevent seizures without side effects.